Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

Barchart · 10/15 05:25

Company Announcement

COPENHAGEN, Denmark; October 15, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 3,016 million in the third quarter of 2024. Net trade sales were USD 1,684 million in the U.S. and USD 1,332 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.  

Read more at globenewswire.com